Myeloma

Treatment Landscape

Multiple myeloma is considered treatable but not curable in most cases, though remission is often achievable. Therapeutic approaches include: Chemotherapy and steroids.

Targeted therapies: proteasome inhibitors (e.g., bortezomib), immunomodulatory drugs (lenalidomide, thalidomide), and monoclonal antibodies (e.g., elotuzumab)

Stem cell transplantation, especially in eligible younger/fit patients.

CAR T-cell therapies targeting BCMA, such as idecabtagene vicleucel (Abecma), a breakthrough gene therapy now FDA-approved for relapsed/refractory myeloma

Supportive treatment with bisphosphonates to prevent bone fractures and pain.

Palliative care early in advanced stages improves quality of life through symptom management

Ongoing research includes AI-based monitoring of minimal residual disease (MRD) for prognostication and treatment decisions.

Has a significant presence in Canada, with thousands diagnosed annually and a continual rise in prevalence.

Benefits from strong advocacy efforts and ongoing clinical helping patients live longer, healthier lives